Displaying 76–100 of 251 results for Paul Thomas, Senior Editor
The veteran microbiologist discussed experimentation with a rapid microbiological CFU counting technique, and maintained that validation should not be significantly different than with traditional methods.
A green chemistry and environmental expert talks about whether pharma is really as green as it thinks it is.
Process modeling and life cycle assessment are helping to gauge the environmental impact of single-use equipment.
Continuous processing and bioprocesses deserve more attention, says GSKs Conchita Jimenez-Gonzalez, who chairs the ACS GCI Pharma Roundtable.
Theres nothing like a good tale of frugality to make your day.
IT, Engineering, Lab? The answer under a consolidated system should be no one and everyone, says Patnis Jim Macdonell.
Abbott's Continuous Improvement Manager shares best practices on how to prepare an organization for Lean and Six Sigma projects.
As paradigms shift, we also need paradigm expansion.
Maxiom Groups Scott Dicks answers our questions about whether drug manufacturers are moving ahead with electronic pedigree programs, software
John Danese, Oracles Director of Product Strategy, provides an update on the electronic pedigree landscape and how manufacturers are doing in their serialization efforts.
Manufacturers electronic pedigree and serialization efforts creep ahead, slowed by FDAs inaction.
The annual spring tradeshow has reenergized itself by building a year-round online presence.
Two viable techniques exist for better lyo control in commercial processes, says UConns freeze-drying guru.
Theres no good way to deliver bad news, but that doesnt mean it should be hidden or glossed over.
Our annual survey results say youve just about had enough. Will 2011 be the year things turn in your favor?
Theres still not enough evidence for full-fledged optimism, says a leading recruiter.
For CEOs, maybe therapy comes with the territory.
Production planning is hard enough, but when uncertainty peaks, the challenges are compounded.
Customized, cheaper immunotherapies could be delivered to patients within a month, says Argos Therapeutics head of manufacturing.
Three experts share their views and best practices of risk-based contract partnerships.
If the serial acquirers dont kill us, theyll make us stronger.
In searching for a model, FDA and EMA need look no further than Canada.
Pfizers John Shabushnig shares insights into burning compendial and regulatory issues.
Win-win aspects must guide any international collaborations, says Japans Toshiyoshi Tominaga.